Adverse effect · Maridebart cafraglutide

How common is GI side effects with Maridebart cafraglutide?

B
Grade B — probable, not settledSame RCT · effect size: large · adverse
Short answerProbable, not settled. Human data exist (Same RCT) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Nausea and vomiting were frequent, particularly without dose escalation; the regimens that started low and stepped up were better tolerated, which is why phase 3 uses escalation.

What the studies show

Nausea and vomiting were frequent, particularly without dose escalation; the regimens that started low and stepped up were better tolerated, which is why phase 3 uses escalation.

“Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.”

Verbatim, from the abstractJastreboff AM, et al. Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial. N Engl J Med, 2025

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Jastreboff AM, et al. Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial.N Engl J Med, 2025592 enrolled; obesity and obesity-diabetes cohorts; 52 weeks. NCT05669599.

In context

Maridebart cafraglutide, or MariTide, is an antibody that blocks the GIP receptor with two GLP-1-agonist peptides attached, injected once a month. In a 592-person phase 2 trial published in the New England Journal of Medicine in 2025, people with obesity lost 12–16% at 52 weeks against 2.5% on placebo. Gut side effects were common, less so with dose escalation. Phase 3 trials are running; it is not approved anywhere.

Maridebart cafraglutide is investigational (phase 3). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Maridebart cafraglutide proven to cause GI side effects?
Not yet settled. Same RCT — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Nausea and vomiting were frequent, particularly without dose escalation; the regimens that started low and stepped up were better tolerated, which is why phase 3 uses escalation.
Is Maridebart cafraglutide approved for this?
No. Maridebart cafraglutide is investigational (phase 3); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Maridebart cafraglutide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →